Grant: Engage Grants Program
Université du Québec à Montréal
$25,000.00
Development of a medicinal chemistry route involving metal-catalyzed reactions for the synthesis of a small set of inhibitors of a selected biological target
FY 2012-13
Summary
Medicinal chemistry is a complex scientific field where the affinity of a synthetic compound for a protein or an
enzyme involved in a disease is optimized through structural and functional modifications at the molecular
level. In order to obtain the desired physiological effect, excellent intrinsic and cellular potency must be
obtained, concomitantly with ideal biophysical properties. In this project, the design of a synthetic route
required for the preparation of the first inhibitors of a selected biological target will be accomplished. This
synthetic sequence will involve metal-catalyzed reactions as the key steps for the preparation of the inhibitors.
The development of metal-promoted transformations involves the optimization of multiple parameters such as
the catalyst, the ligands, the base, and the solvent and requires an in-depth knowledge of transition metal
chemistry, an expertise that we have in our group. Once in place, this route will serve in the synthesis of a
limited number of analogues which will be tested against the company's selected enzyme. A preliminary
Structure-Activity-Relationship (SAR) study will be performed using a small set of analogues in order to
identify key pharmacophores involved in the binding of the inhibitor. Our knowledge in synthetic organic
chemistry, more specifically in transition metal-promoted transformations, and medicinal chemistry will fill a
need within Delmar Chemicals and will complement their expertise on large scale production of
pharmaceutical ingredients. The Canadian economy depends on the strength of high technological fields such
as the pharmaceutical and medicinal sciences. Companies working in those fields rely on fundamental research
in organic and medicinal chemistry and on the expertise found in academia. This project will have
considerable repercussions by helping Delmar Chemicals in driving their first fundamental medicinal chemistry
project and in attracting new contracts of this kind, thus directly impacting the Canadian economy and job
perspectives.
Program
Engage Grants Program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
437993-2012
Name nom
Gagnon, Alexandre
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Development of a medicinal chemistry route involving metal-catalyzed reactions for the synthesis of a small set of inhibitors of a selected biological target
Keyword
NSERC
Application summary
Medicinal chemistry is a complex scientific field where the affinity of a synthetic compound for a protein or an
enzyme involved in a disease is optimized through structural and functional modifications at the molecular
level. In order to obtain the desired physiological effect, excellent intrinsic and cellular potency must be
obtained, concomitantly with ideal biophysical properties. In this project, the design of a synthetic route
required for the preparation of the first inhibitors of a selected biological target will be accomplished. This
synthetic sequence will involve metal-catalyzed reactions as the key steps for the preparation of the inhibitors.
The development of metal-promoted transformations involves the optimization of multiple parameters such as
the catalyst, the ligands, the base, and the solvent and requires an in-depth knowledge of transition metal
chemistry, an expertise that we have in our group. Once in place, this route will serve in the synthesis of a
limited number of analogues which will be tested against the company's selected enzyme. A preliminary
Structure-Activity-Relationship (SAR) study will be performed using a small set of analogues in order to
identify key pharmacophores involved in the binding of the inhibitor. Our knowledge in synthetic organic
chemistry, more specifically in transition metal-promoted transformations, and medicinal chemistry will fill a
need within Delmar Chemicals and will complement their expertise on large scale production of
pharmaceutical ingredients. The Canadian economy depends on the strength of high technological fields such
as the pharmaceutical and medicinal sciences. Companies working in those fields rely on fundamental research
in organic and medicinal chemistry and on the expertise found in academia. This project will have
considerable repercussions by helping Delmar Chemicals in driving their first fundamental medicinal chemistry
project and in attracting new contracts of this kind, thus directly impacting the Canadian economy and job
perspectives.